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David Gisselquist, John Potterat and Stuart Brody, writing
recently in the SAMJ,1 suggest that the high prevalence of HIV
among infants and children in sub-Saharan Africa is a result of
iatrogenic transmission of HIV, rather than mother-to-child
transmission (MCTC). Earlier, the same group have suggested
that unsafe injections are a major, if not the main, mode of
transmission of HIV-1 in sub-Saharan Africa.2,3
Certainly there are definite cases of unexplained HIV-1
infection in children.4 Hiemstra et al. have documented 14 cases
of unexplained HIV-1 infection, 12 from the Western Cape and
1 each from the Eastern Cape and KwaZulu-Natal. Thirteen
children (92%) had been hospitalised previously. Eight
hospitals were identified in the Western Cape. Ten of 13
children had been admitted as neonates and 9 of 13 had had 2
or more admissions. All but 2 of the children had been
subjected to intravascular cannulation and intravenous drug
administration before the diagnosis of HIV. This is certainly
circumstantial evidence of nosocomial transmission, but the
authors do not necessarily regard this mode of transmission as
responsible for most HIV-1 transmission in South Africa.
A study of safe injection practices in health facilities in
Swaziland5 shows that although disposable syringes are always
used in the health care facilities studied, there are certainly
cases of unsafe injection practice that could lead to nosocomial
infections with HIV and hepatitis.
So, the question remains — to what extent are unsafe
injection practices responsible for transmitting HIV and other
blood-borne diseases in sub-Saharan Africa? Gisselquist and
his colleagues are quite convinced that this mode of
transmission is so important that they are concerned that too
much money will be put into safe-sex campaigns and not
enough into ensuring sterile procedures and safe injection
technique. However, George Schmid and colleagues, in
reviewing the epidemiological literature, conclude that
Gisselquist’s group put too much emphasis on the role of
unsafe injections in the transmission of HIV-1.6 Their
arguments hinge on a full examination of the Gisselquist
group’s assumptions.
The first of these assumptions is that unsafe injections are
common in Africa, the Gisselquist group quoting figures of up
to 50% of all injections being given with re-used needles. This
figure is challenged by Schmid’s group, who quote a figure of
18% in Africa. They point out that most injections in Africa are
intramuscular, and that the amount of HIV remaining on a
used needle in these circumstances would almost certainly be
too small to cause infection. They also point out that simple
sterilisation techniques, almost universally used where needles
and syringes are reused, would decrease the chances of cross-
infection still further.
Gisselquist et al.’s SAMJ article concentrates on paediatric
HIV-1 infection, the main argument being that there are too
many cases of HIV-1 among infants to be accounted for by
vertical transmission alone. However, Schmid et al. identified 6
population-based studies on the prevalence of HIV-1 infection
in sub-Saharan Africa that included children. These studies all
found that the prevalence of infection in children aged 5 to 14
years — an age range that is less likely to have acquired the
infection from their mother — was much lower than the
prevalence in adolescents and adults aged 15 years or older. If
injections were the major mode of transmission, the authors
would have expected a much smaller discrepancy between
HIV-1 prevalence in children and adults, as there is no
evidence that children have fewer injections than adolescents
and adults. They also point out that longitudinal studies show
that seroconversion in uninfected children is rare, quoting a
study in Uganda that showed only one seroconversion among
5 451 HIV-1 negative infants and children aged 0 - 12 years,
followed up for 8 596 person-years. In Cote d’Ivoire, none of
the children born to 266 persistently HIV-1 negative mothers
seroconverted over 48 months of follow-up. Indeed, Hiemstra
et al. found only 14 cases of unexplained HIV-1 infection in
their recent survey, although more may be uncovered in later
research.
Gisselquist et al. quote the results of a national survey of
South African children7 and adults that suggested an
unexpectedly high prevalence of 5.6% among 2 - 12-year-olds
as being further evidence of transmission through unsafe
injection. However, as Schmid et al. point out, there are many
questions about the validity of the survey’s findings, discussed
by the survey authors but largely disregarded by Gisselquist’s
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group. For example, there was no increase in prevalence of
infection in children by age. The non-response rate in the
survey was high because 29% of the listed visiting points and
37% of eligible respondents in the remaining households did
not participate. The survey results are questionable in other
ways; prevalence among children by race is the opposite of that
shown by other surveillance and death registration data, and
the HIV-1 pattern by provinces in the survey was also
inconsistent with surveillance and previous research. The
survey also provides no evidence that AIDS is nearly as
important a cause of mortality among children and teenagers
as the survey numbers would suggest. 
When the Gisselquist group’s first set of papers came out,
they were reported by the world’s media somewhat
uncritically as evidence that unsafe sex was not the primary
mode of transmission of HIV-1 transmission in sub-Saharan
Africa. Already, the US Senate Committee on Health,
Education, Labor and Pensions have held hearings to decide
whether HIV/AIDS funds should be devoted to programmes
that target unsafe injections rather than unsafe sex. The danger
of taking Gisselquist’s research in an uncritical way is that it
may lead to a reduction in the impact of the message that
unsafe sex transmits HIV-1 — something for which the
evidence is compelling if examined carefully and
systematically. That is not to say that we should take no notice
of the documented problems around the re-use of disposable
syringes. But the emphasis should be placed purely on
ensuring sterile technique, and scarce resources should not be
devoted to research into the extent of nosocomial transmission
of HIV-1.
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Today, following a few decades of manufacturing advances, an
expanding range of insulin preparations is being used to meet
the short-acting and basal requirements of patients with
diabetes.
Because of the frequently dangerous confusion caused by
innumerable products on the world’s markets, with their
different concentrations, brand names, haphazard and
unmatching colour codes and alternative delivery devices —
made worse by the recent availability of a whole family of new
insulin analogues — the International Diabetes Federation and
the World Health Organisation (WHO) have long advocated a
uniform system of international product recognition on a
universal scale to minimise therapeutic errors known to
happen frequently.1
As from now South Africa will start to benefit from this
initiative in which all players, including all major insulin
manufacturers, fulfil a responsible role for the common good of
the world’s diabetic community. Thankfully we are already a
single-strength market following the successful changeover to
the U-100 insulins 20 years ago.2
For the greater safety of our patients we now have to
endorse the universal colour code for the four most frequently
prescribed human insulin ranges, namely regular/soluble,
NPH isophane, lente and biphasic 30/70 mixtures.3 This will
only apply to the multinational-sourced innovator insulins and
not to the possibly less effective generics that may one day
Making insulin usage safer — the universal colour code
François Bonnici is Professor Emeritus at the University of Cape
Town Faculty of Health Sciences and Co-Director of the Diabetes
Clinical Trials Unit, President of Diabetes South Africa, Member
of the WHO Expert Panel on Diabetes and Chairperson of the
Local Organising Committee of the Cape Town 2006 World
Diabetes Congress.
